Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Juno Therapeutics, Inc.. (2/29/16). "Press Release: Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results". Seattle, WA.

Organisations Organisation Juno Therapeutics Inc.
  Group Celgene (Group)
  Organisation 2 Stage Cell Therapeutics GmbH
  Today Juno Therapeutics GmbH
  Group Celgene (Group)
Product Product  lisocabtagene maraleucel (liso-cel; JCAR017)
  Index term 2 Stage Cell Therapeutics–Juno Therapeutics: investment, 201505 acquisition remaining 95% for €52.5m cash upfront + 486.3k shares + €135m milestones
Person Person Bishop, Hans E. (Juno Therapeutics 201601 CEO + Co-Founder before Dendreon + Bayer + GW + SKB)
     


   
Record changed: 2017-10-01

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Celgene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top